AU2017221295B2 - ST-246 ( Tecovirimat monohydrate) suspension formulations - Google Patents

ST-246 ( Tecovirimat monohydrate) suspension formulations Download PDF

Info

Publication number
AU2017221295B2
AU2017221295B2 AU2017221295A AU2017221295A AU2017221295B2 AU 2017221295 B2 AU2017221295 B2 AU 2017221295B2 AU 2017221295 A AU2017221295 A AU 2017221295A AU 2017221295 A AU2017221295 A AU 2017221295A AU 2017221295 B2 AU2017221295 B2 AU 2017221295B2
Authority
AU
Australia
Prior art keywords
dry suspension
simethicone
methylcellulose
formulation
tecovirimat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017221295A
Other languages
English (en)
Other versions
AU2017221295A1 (en
Inventor
Melialani A.C.L.S. Anderson
Kris Holt
Dennis E. Hruby
Ying Tan
Shanthakumar R. Tyavanagimatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siga Technologies Inc
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of AU2017221295A1 publication Critical patent/AU2017221295A1/en
Application granted granted Critical
Publication of AU2017221295B2 publication Critical patent/AU2017221295B2/en
Priority to AU2022218556A priority Critical patent/AU2022218556B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2017221295A 2016-02-16 2017-02-15 ST-246 ( Tecovirimat monohydrate) suspension formulations Active AU2017221295B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022218556A AU2022218556B2 (en) 2016-02-16 2022-08-18 ST-246 ( Tecovirimat monohydrate) suspension formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662295710P 2016-02-16 2016-02-16
US62/295,710 2016-02-16
PCT/US2017/017915 WO2017142910A1 (en) 2016-02-16 2017-02-15 St-246 ( tecovirimat monohydrate) suspension formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022218556A Division AU2022218556B2 (en) 2016-02-16 2022-08-18 ST-246 ( Tecovirimat monohydrate) suspension formulations

Publications (2)

Publication Number Publication Date
AU2017221295A1 AU2017221295A1 (en) 2018-07-12
AU2017221295B2 true AU2017221295B2 (en) 2022-05-19

Family

ID=59625432

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017221295A Active AU2017221295B2 (en) 2016-02-16 2017-02-15 ST-246 ( Tecovirimat monohydrate) suspension formulations
AU2022218556A Active AU2022218556B2 (en) 2016-02-16 2022-08-18 ST-246 ( Tecovirimat monohydrate) suspension formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022218556A Active AU2022218556B2 (en) 2016-02-16 2022-08-18 ST-246 ( Tecovirimat monohydrate) suspension formulations

Country Status (8)

Country Link
US (2) US11433051B2 (enExample)
EP (1) EP3416637A4 (enExample)
JP (2) JP7074677B2 (enExample)
CN (1) CN108430469A (enExample)
AU (2) AU2017221295B2 (enExample)
CA (1) CA3013937A1 (enExample)
IL (1) IL260229B2 (enExample)
WO (1) WO2017142910A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017221295B2 (en) * 2016-02-16 2022-05-19 Siga Technologies, Inc. ST-246 ( Tecovirimat monohydrate) suspension formulations
WO2018049184A1 (en) 2016-09-09 2018-03-15 Cutispharma, Inc. Suspensions and diluents for metronidazole and baclofen
CN115141136B (zh) * 2021-03-31 2023-06-20 中国人民解放军军事科学院军事医学研究院 特考韦瑞药的共晶及其制备方法
JP7546138B2 (ja) * 2021-12-21 2024-09-05 上海奥全生物医葯科技有限公司 固形剤形を水に分散させて懸濁液を形成する方法、懸濁液および固体剤形を投与する方法
CN116625971A (zh) * 2023-04-11 2023-08-22 北京达因高科儿童药物研究院有限公司 一种西甲硅油口溶膜中二甲硅油和二氧化硅含量的检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101011360A (zh) * 2007-02-05 2007-08-08 深圳致君制药有限公司 干混悬剂的处方组成及其制备方法
CN102406617A (zh) * 2011-11-30 2012-04-11 中国人民解放军军事医学科学院生物工程研究所 一种替韦立马干混悬剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043747A (en) * 1958-10-22 1962-07-10 Upjohn Co Tablets coated with carboxymethylcellulose shellac composition
US4863737A (en) * 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
ES2043766T3 (es) * 1987-11-11 1994-01-01 Pharmascience Lab Una nueva composicion farmaceutica que comprende exifona y un polimero soluble en agua.
FR2705966B1 (fr) * 1993-06-04 1995-08-25 Dow Corning Sa Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
CA2793533C (en) 2010-03-23 2019-02-26 Siga Technologies, Inc. Polymorphic forms of st-246 and methods of preparation
CN102532901A (zh) 2010-12-21 2012-07-04 重庆北碚现代应用药物研究所 一种西甲硅油的制备方法
CN105055326B (zh) 2015-07-17 2018-02-06 西南大学 西甲硅油干混悬剂及其制备方法
AU2017221295B2 (en) * 2016-02-16 2022-05-19 Siga Technologies, Inc. ST-246 ( Tecovirimat monohydrate) suspension formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101011360A (zh) * 2007-02-05 2007-08-08 深圳致君制药有限公司 干混悬剂的处方组成及其制备方法
CN102406617A (zh) * 2011-11-30 2012-04-11 中国人民解放军军事医学科学院生物工程研究所 一种替韦立马干混悬剂及其制备方法

Also Published As

Publication number Publication date
JP7297858B2 (ja) 2023-06-26
EP3416637A1 (en) 2018-12-26
EP3416637A4 (en) 2019-11-06
CN108430469A (zh) 2018-08-21
WO2017142910A1 (en) 2017-08-24
IL260229B2 (en) 2023-06-01
IL260229A (en) 2018-07-31
US11433051B2 (en) 2022-09-06
US11779566B2 (en) 2023-10-10
AU2017221295A1 (en) 2018-07-12
AU2022218556A1 (en) 2022-09-15
JP2022031345A (ja) 2022-02-18
US20210212987A1 (en) 2021-07-15
CA3013937A1 (en) 2017-08-24
US20230016581A1 (en) 2023-01-19
AU2022218556B2 (en) 2024-08-15
JP7074677B2 (ja) 2022-05-24
JP2019511465A (ja) 2019-04-25

Similar Documents

Publication Publication Date Title
AU2022218556B2 (en) ST-246 ( Tecovirimat monohydrate) suspension formulations
JP6092629B2 (ja) リファキシミン使用準備済懸濁液
JP7503632B2 (ja) 液体タシメルテオン製剤及びそれを使用する方法
JP4264105B2 (ja) イソソルビド含有ゼリー製剤
JPWO2015152190A1 (ja) セファロスポリンエステルを含む粒状固形製剤およびその製造方法
JP2015199721A (ja) セファロスポリンエステルを含む粒状固形製剤およびその製造方法
ES2763321T3 (es) Premezcla y composición farmacéutica para la administración oral de memantina como una suspensión permanente o de preparación previa a la administración al paciente, optativamente por sonda de alimentación enteral y procedimientos correspondientes
US20110117193A1 (en) Antiretroviral drug formulations for treatment of children exposed to hiv/aids
EP2468254A1 (en) Orally disintegrating tablet having a taste masking effect
AU2007284644A1 (en) Compositions and methods for increasing blood platelet levels in humans
EP3377044B1 (en) Ibuprofen compositions for direct oral administration
RU2806302C1 (ru) Содержащие тасимелтеон жидкие препараты и способы их применения
KR101458670B1 (ko) 분지쇄아미노산을 함유하는 약제학적 조성물 및 그 제조방법
EP2558079B1 (en) Ciprofloxacin dry syrup composition
Singh et al. Taste masking of bitter drugs in pharmaceutical suspension: A review
WO2006096182A1 (en) Azithromycin powder for oral suspension compositions
CN107260687A (zh) 硫唑嘌呤干混悬剂及其制备方法
CN121194776A (zh) 马立巴韦组合物和其用途
JP2010013357A (ja) 高含量l−カルボシステインドライシロップ剤
Jethara Patented Pharmaceutical Reconstitutable Sustained Release Suspension

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)